Written by 
ismagilov/iStock via Getty Images J.P. Morgan has initiated coverage of Septerna (NASDAQ:SEPN) with an overweight rating, citing the company’s platform for GPCR drug design. “Notwithstanding manifold newly actionable GPCR targets, we see Septerna (SEPN) executing a highly attractive pipeline strategy, focused on validated targets Source link
